
Please try another search
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Johan Heilborn | - | - | Member of Scientific Advisory Board |
Lennart Emtestam | - | - | Member of Scientific Advisory Board |
Howard J. Maibach | - | - | Member of Scientific Advisory Board |
Jan Faergemann | - | - | Member of Scientific Advisory Board |
Bernt Lindelöf | - | - | Member of Scientific Advisory Board |
Richard Ding | - | 2025 | Independent Director |
Jonas Ekblom | 60 | 2024 | Executive Chairman |
Otto Skolling | 64 | 2025 | Director |
Isabelle Valerie Ghislaine Ducellier | 56 | 2025 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review